Hemispherx $HEB Ramping Up Manufacturing to Pursue Multi-Billion Dollar Immuno-Oncology Market
13 May
2019
Written by Mike Elliott

Hemispherx $HEB Ramping Up Manufacturing to Pursue Multi-Billion Dollar Immuno-Oncology Market »

In this episode of CEOLIVE we’re joined by Mr. Thomas Equels, CEO of Hemispherx Biopharma, which trades on the NYSE under ticker HEB. Hemispherx is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.

Read more...

Login

Lost your password?